CD80–CD28 co-stimulatory receptor-ligand interaction (CD80–CD28)

The CD80–CD28 co-stimulatory receptor-ligand interaction is a fundamental checkpoint in the adaptive immune response, providing the "Signal 2" necessary for full T cell activation (StatPearls, 2023). CD80 (also known as B7-1) is a glycoprotein expressed on activated antigen-presenting cells (APCs), such as dendritic cells and B cells, which binds to the CD28 receptor constitutively expressed on T cells (UniProt P33681; UniProt P16410). This binding triggers intracellular signaling pathways, including the PI3K/Akt and Ras/MAPK pathways, which promote T cell proliferation, survival, and the production of cytokines like interleukin-2 (PubMed: 29427385). In the absence of this co-stimulatory signal, T cell receptor (TCR) engagement alone can lead to anergy or immune tolerance. This interaction is a primary target for therapeutic intervention in autoimmune disorders and organ transplantation, where drugs like Abatacept and Belatacept act as decoys to block the binding of CD80 to CD28, thereby inducing immunosuppression (NIH: Drug Record). Conversely, the pathway is central to cancer immunotherapy, as the inhibitory receptor CTLA-4 competes with CD28 for CD80 binding; blocking CTLA-4 with antibodies like Ipilimumab allows the CD80–CD28 interaction to proceed, enhancing anti-tumor T cell activity (PubMed: 30108319). Therapeutic modulation of this axis requires careful management, as over-activation can lead to cytokine release syndrome, while excessive inhibition increases the risk of serious opportunistic infections and certain malignancies.

Other names

B7-1/CD28 interactionCD80/CD28 pathwayT-cell co-stimulation axisB7:CD28 complexCD80-CD28 costimulatory signal

Drugs targeting this interaction primarily function as selective co-stimulation modulators. Soluble fusion proteins (CTLA-4-Ig), such as Abatacept and Belatacept, bind to CD80/CD86 on antigen-presenting cells with higher affinity than CD28, effectively blocking the co-stimulatory signal and inhibiting T cell activation. Monoclonal antibodies may also target CD28 directly to either block its function or, in the case of superagonists like Theralizumab, bypass the need for TCR signaling to activate T cells. Additionally, checkpoint inhibitors like Ipilimumab block CTLA-4, preventing it from outcompeting CD28 for CD80 binding, thereby maintaining the co-stimulatory signal for anti-tumor immunity.